SMC Says Yes to Lemtrada(R)a- 1/4 (alemtuzumab) 12mg IV, a New Treatment for Adults with Active Relapsing Remitting-Multiple Sclerosis (RRMS)
Market Watch, The Wall Street Journal, 7 Jul 2014
Accessed on 9 Jul 2014 from http://www.marketwatch.com/story/smc-says-yes-to-lemtradara-14-alemtuzumab-12mg-iv-a-new-treatment-for-adults-with-active-relapsing-remitting-multiple-sclerosis-rrms-2014-07-07.